Cardiff Oncology Inc. (NASDAQ:CRDF) does about 748.63K shares in volume on a normal day but saw 378128 shares change hands in Wednesday trading. The company now has a market cap of 92.46M USD and an enterprise value of about $89.66M. Its current market price is $4.38, marking a decrease of -1.79% compared to the previous close of $4.46. The 52 week high reached by this stock is $5.75 whilst the lowest price level in 52 weeks is $0.70. The script in recent trading has seen the stock touch a high of $4.5689 and a low of $4.42.
Cardiff Oncology Inc. (CRDF) has a 20-day trading average at $4.61 and the current price is -23.83% off the 52-week high compared with 524.82% distance from its 52-week low. The 50-day simple moving average of the closing price is $3.69 and its 200-day simple moving average is $1.94. If we look at the stock’s price movements over the week, volatility stands at 7.58%, which increases to 10.03% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 50.20 to suggest the stock is neutral.
2 analysts observing the Cardiff Oncology Inc. (CRDF) stock have set the 12-month price targets for the company’s shares at between $6.00 and $23.00. The median price target is 69.79% away from the current levels at $14.50.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The current price level is -5.52%, 20.22%, and 127.33% away from its SMA20, SMA50, and SMA200 respectively, with the CRDF price moving below the 50-day SMA on July 28. Cardiff Oncology Inc. (CRDF) stock is down -1.76% over the week and -12.03% over the past month. Its price is 259.68% year-to-date and 147.78% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2019, with the company’s earnings per share (EPS) of -$0.51 above consensus estimates by $0.06. The company’s next earnings report is expected on 07/31/2020, with forecasts estimating quarterly EPS at $0 and -$1.07 for whole year. CRDF’s earnings per share are forecast to grow by 61.80% this year and 0.90% over next year.
Its 12-month price target is $14.50. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $6.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $23.00.
Outstanding shares total 9.91M with insiders holding 0.19% of the shares and institutional holders owning 11.40% of the company’s common stock. The company has a return on investment of -228.50%. The beta has a value of 1.45. Price to book ratio is 7.19 and price to sales ratio is 308.19.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in Cardiff Oncology Inc. (CRDF) to 216,695 shares, mirroring a recent drop by 0.00%. Vanguard Total Stock Market Index dumped 0.0 shares of Cardiff Oncology Inc. common stock bringing its total worth to about $1.09 million at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which sold off 0.0 shares to end up with 77,584 shares worth $0.39 million. Fidelity Extended Market Index Fu raise their holdings by 149.86% in the company over the course of the most recent quarter. It now holds a 0.20% position in Cardiff Oncology Inc. thanks to 39506.0 shares amounting to $0.2 million.